Advances in Antifungal Drugs

Dear Colleagues,

Fungal infections cause milions of death world wide each year. Candida spp. and Aspergillus spp. are among the two principal opportunistic fungi associated with high mortality rates and detrimental impacts on healthcare resources. The population at risk of acquiring an invasive fungal infection is increasing at an alarming pace as the rates of antifungal resistance rise. This is primarily true in Candida spp., especially for azole resistance in Candida parapsilosis and echinocandin resistance in Candida glabrata, but also for azole resistance in Aspergillus fumigatus. In order to better highlight the magnitude of the problem, the WHO has recently released the fungal pathogen priority list to point out the direction future research should pursue. To this point, scholars should aim for the discovery of new molecules. The optimization of existing therapeutic strategies and the clinical evaluation of the potential and effectiveness of the new antifungal molecules recently introduced in the antifungal pipeline are of outmost importance and therefore will constitute the primary focus of this Special Issue.

Dr. Antonella Lupetti
Dr. Iacopo Franconi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• new antifungal drugs
• antifungal resistance
• antifungal therapy
• Candida spp. infections
• Aspergillus spp. infections
• fungal infections
• antifungal compounds